A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Gsk Investigational Site
Westmead, New South Wales, Australia
Fiona KwokRecruiting - Gsk Investigational Site
Woolloongabba, Queensland, Australia
Nirija AndersonRecruiting - Gsk Investigational Site
Box Hill, Victoria, Australia
Brendan WisniowskiRecruiting - Gsk Investigational Site
Frankston, Victoria, Australia
Patricia WalkerRecruiting
- Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 24 Jun 2026
- Primary completion
- 12 Jan 2033
- Completion
- 12 Jan 2033
- Last update posted
- 17 Jul 2026
- Registered enrollment
- 60
- Registry id
- NCT07224672
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.